GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Research & Development

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Research & Development : €41.97 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. ImmuneOnco Biopharmaceuticals (Shanghai)'s Research & Development for the six months ended in Jun. 2024 was €15.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €41.97 Mil.


ImmuneOnco Biopharmaceuticals (Shanghai) Research & Development Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Research & Development Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Research & Development
24.45 37.55 37.49 42.34

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial 21.80 16.51 21.04 15.26 26.71

ImmuneOnco Biopharmaceuticals (Shanghai) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €41.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuneOnco Biopharmaceuticals (Shanghai)  (FRA:R9Z) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


ImmuneOnco Biopharmaceuticals (Shanghai) Research & Development Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Traded in Other Exchanges
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines